



Laurie A. Burlingame

Member

Direct **781-697-2200**

Waltham, MA

lburlingame@morse.law

Laurie is a member of the Firm's Corporate Practice Group. She counsels clients across the life sciences and technology industries in a wide range of transactional matters, including venture capital and debt financings, mergers and acquisitions, licensing and strategic collaborations, supply and manufacturing arrangements and capital market transactions. Laurie also serves as trusted outside general counsel to emerging and established private and public companies. In such role, she advises management teams and boards of directors on numerous matters across the corporate lifecycle, including formation and founder issues, corporate governance, structuring matters, research and commercial contracting, and disclosure obligations.

Laurie's clients include pharmaceutical, medical device, diagnostics, biological materials and tools, AI, and other technology companies. She also represents venture capital firms and hedge funds in connection with their portfolio investments.

Active in the community, Laurie serves as a Lecturer of Law at Boston University School of Law and serves on the boards of directors of Families for Depression Awareness and Girls Inc. of Boston and Lynn. She is also a frequent mentor and speaker for university and incubator programs and maintains active membership in local technology and medical associations, including Women in Bio. Laurie has also received several awards for dedication to pro bono service,

Prior to joining Morse, Laurie was a partner in the corporate business and transactions group at Morgan Lewis & Bockius LLP. Before Morgan Lewis, Laurie was a partner in the technology and life sciences group at Goodwin Procter LLP.

Education

Harvard Law School, 2006, J.D.

Clark University, 2003, M.B.A.

Harvard University School of Arts and Sciences, 2002, M.A.

Wellesley College, 1999, B.A., summa cum laude

Admissions

Massachusetts Bar

U.S. Patent & Trademark Office

Practice Areas

Corporate

Mergers & Acquisitions

Public Company Representation

Startups & Emerging Companies

Venture Capital

Industries

AI and Robotics
HealthTech
Life Sciences
Medical Devices
Software-as-a-Service

- Initial public offering and follow-on offerings for a company focused on developing treatments for NASH and Long COVID
- An operating company in the ophthalmology space in connection with its deSPAC transaction
- A SPAC in its deSPAC with a next-generation of radiopharmaceuticals company
- A SPAC in its deSPAC transaction with a regenerative medicine company

* Represents transactions completed prior to joining Morse.

Publications

A Look-Back at the BioPharma Industry in 2025

Confidentiality Agreements 101 for Entrepreneurs

Five Tips and Tricks for Conquering the 2026 J.P. Morgan Healthcare Conference